Brief: Arjo Receives 510K Clearance From US FDA For Woundexpress
06/09/2021 07:55
Sept 6 (Reuters) - Arjo AB (publ) ARJOb.ST :
* RECEIVES 510(K) CLEARANCE FROM US FDA FOR WOUNDEXPRESS
* WOUNDEXPRESS IS EXPECTED TO BE LAUNCHED IN US DURING Q1
2022
Source text for Eikon: ID:nWkr2gFCsL
Further company coverage: ARJOb.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Arjo AB (publ)
See all newsBrief: Arjo Q1 Adjusted EBITDA Down At SEK 456 Mln
Sweden's Arjo misses Q4 revenue and profit estimates on currency swings, tariffs
Brief: Arjo Proposes Dividend Per Share Of SEK 0.95
Brief: Arjo Q3 Adjusted EBITDA SEK 436 Million Vs. IBES Estimate SEK 455.4 Million
Brief: Christofer Carlsson Appointed Permanent CFO Of Arjo